7

9

14

16

17

1:

PATENT APPLN. NO. 08/487,623 RESPONSE UNDER 37 C.F.R. § 1.115

- reacting microparticles coated with a bioaffinity reactant A which specifically binds [an] at least one analyte to be assayed, a sample to be analyzed, and a labelled bioaffinity reactant B to cause said analyte and said labelled bioaffinity reactant B to specifically bind to said microparticles via the bioaffinity reactant A; and
- measuring signal strength from labelled bioaffinity reactant B bound to the microparticles to determine the analyte concentration in the sample, the improvement comprising: 10
- contacting a predetermined amount of said sample, predetermined number of uniformly sized microparticles coated with said bioaffinity reactant A and said labelled bioaffinity reactant B labelled with a luminescent label such that, after the specific binding of the analyte in the sample to said predetermined number of uniformly sized microparticles, each individual microparticle emits signal strength that corresponds the analyte concentration in the sample , and
- [determining the analyte concentration in said sample by] 19 measuring the signal strength from an individual [microparticles] 20 microparticle using a measuring means capable of reading the 21 luminescence an individual microparticle from 22 microparticles, the number of individual microparticles measured 23 being the minimum number that will provide a statistically reliable 20 measurement of the signal strength], and determining the analyte 25

PATENT APPLN. NO. 08/487,623 RESPONSE UNDER 37 C.F.R. § 1.115

PATENT

Oliver

concentration in the sample by comparing said signal strength 26 measured from said individual microparticle with a standardization 27 curve, wherein said standardization curve is a mean of the signal 26 strength of said predetermined number of uniformly sized 29 microparticles.

02

- 16. (Amended) The assay method according to claim 13, wherein the assay comprises a competitive immunoassay, in which the labelled bioaffinity reactant B [is] comprises an antigen, and the bioaffinity reactant A [comprises] is an antibody for whose binding sites the labelled antigen and [an antigen of] the analyte compete.
- 6. (Twice Amended) The assay method according to claim 13, wherein the assay comprises a non-competitive immunoassay, in which the labelled bioaffinity reactant B [is] comprises an antibody [directed against an antigen of] which specifically binds to the analyte.



7. (Twice Amended) The assay method according to claim 13, wherein the assay comprises a nucleic acid hybridization assay, in which the labelled bioaffinity reactant B [is] comprises a nucleic acid probe which specifically hybridizes with the analyte.

Cancel claims 14, 15 and 8.